CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors
- 1 July 2010
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 185 (1), 532-541
- https://doi.org/10.4049/jimmunol.0903624
Abstract
The selective targeting of the tumor-associated death-inducing receptors DR4 and DR5 with agonistic mAbs has demonstrated preclinical and clinical antitumor activity. However, the cellular and molecular mechanisms contributing to this efficacy remain poorly understood. In this study, using the first described C57BL/6 (B6) TRAIL-sensitive experimental tumor models, we have characterized the innate and adaptive immune components involved in the primary rejection phase of an anti-mouse DR5 (mDR5) mAb, MD5-1 in established MC38 colon adenocarcinomas. FcR mediated cross-linking of MD5-1 significantly inhibited the growth of MC38 colon adenocarcinomas through the induction of TRAIL-R–dependent tumor cell apoptosis. The loss of host DR5, TRAIL, perforin, FasL, or TNF did not compromise anti-DR5 therapy in vivo. By contrast, anti-DR5 therapy was completely abrogated in mice deficient of B cells or CD11c+ dendritic cells (DCs), providing the first direct evidence that these cells play a critical role. Importantly, the requirement for an intact B cell compartment for optimal anti-DR5 antitumor efficacy was also observed in established AT-3 mammary tumors. Interestingly, MD5-1–mediated apoptosis as measured by early TUNEL activity was completely lost in B cell-deficient μMT mice, but intact in mice deficient in CD11c+ DCs. Overall, these data show that Ab-mediated targeting of DR5 triggers tumor cell apoptosis in established tumors in a B cell-dependent manner and that CD11c+ DCs make a critical downstream contribution to anti-DR5 antitumor activity.This publication has 33 references indexed in Scilit:
- TRAIL receptor signalling and modulation: Are we on the right TRAIL?Cancer Treatment Reviews, 2009
- A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cellsEuropean Journal of Immunology, 2008
- Targeting TRAIL death receptorsCurrent Opinion in Pharmacology, 2008
- Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistProceedings of the National Academy of Sciences of the United States of America, 2008
- Combination antibody‐based cancer immunotherapyCancer Science, 2007
- TRAIL-R as a Negative Regulator of Innate Immune Cell ResponsesImmunity, 2004
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyThe Journal of Experimental Medicine, 2004
- Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody TherapyThe Journal of Experimental Medicine, 2004
- Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor DevelopmentThe Journal of Experimental Medicine, 2002
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994